EYEPOINT PHARMACEUTICALS, INC.
480 Pleasant Street
Watertown, MA 02472
August 14, 2024
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Benjamin Richie
| Re: | EyePoint Pharmaceuticals, Inc. |
Registration Statement on Form S-3
Filed August 8, 2024
File No. 333-281391
Request for Acceleration of Effective Date
Dear Benjamin Richie:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, EyePoint Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on August 16, 2024, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted.
| Very truly yours,
| ||
| EyePoint Pharmaceuticals, Inc.
| ||
| By: |
/s/ Ron Honig | |
| Name: |
Ron Honig | |
| Title: |
Chief Legal Officer | |